We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Whistleblower Advocates Against Use of Cox-2 Drugs
FDA Whistleblower Advocates Against Use of Cox-2 Drugs
September 19, 2006
An FDA employee who has publicly criticized the agency for not doing more to protect the public against the cardiovascular health risks associated with Vioxx is calling for patients to take naproxen instead of Cox-2 drugs and is urging the agency to reject Merck’s Vioxx successor Arcoxia, in an editorial recently published in the Journal of the American Medical Association.